Back

Decrease of ECG hypertrophy indices during mavacamten treatment in obstructive hypertrophic cardiomyopathy

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Robert Sepp

University of Szeged, Szeged (Hungary)

6 More presentations in this session

Presentation thumbnail
Characterisation of interrelations among myocardial work parameters in patients with hypertrophic cardiomyopathy: differences between non-obstructive and obstructive disease
Doctor A. Kormanyos (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
The role of stress echocardiography to unmask latent LVOT obstruction in hypertrophic cardiomyopathy
Doctor D. Faro (Catania, IT)
Abstract Slides Video
Presentation thumbnail
Long-term efficacy of mavacamten on cardiac structure and function in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial
Doctor Z. Tian (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
The influence of genotype on the phenotype and prognosis of patients with hypertrophic cardiomyopathy
Miss I. Conde (Braga, PT)
Abstract Slides Video
Presentation thumbnail
Examining ECG's performance as a screening method for hypertrophic cardiomyopathy: phenotypic correlations and evaluation
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Assessment of changes in right-sided cardiac echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment
thumbnail
Congress Presentation
Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment
thumbnail
Congress Presentation
Temporal changes in echocardiographic parameters of diastolic dysfunction in obstructive hypertrophic cardiomyopathy during mavacamten treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources